MX357504B - Derivado de feniltriazol y su uso para modular complejo del receptor gabaa. - Google Patents
Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.Info
- Publication number
- MX357504B MX357504B MX2014014871A MX2014014871A MX357504B MX 357504 B MX357504 B MX 357504B MX 2014014871 A MX2014014871 A MX 2014014871A MX 2014014871 A MX2014014871 A MX 2014014871A MX 357504 B MX357504 B MX 357504B
- Authority
- MX
- Mexico
- Prior art keywords
- triazole derivative
- modulating
- receptor complex
- phenyl triazole
- gabaa receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664287P | 2012-06-26 | 2012-06-26 | |
| DKPA201270368 | 2012-06-26 | ||
| PCT/EP2013/063193 WO2014001281A1 (en) | 2012-06-26 | 2013-06-25 | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014014871A MX2014014871A (es) | 2015-06-17 |
| MX357504B true MX357504B (es) | 2018-07-12 |
Family
ID=49782299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014871A MX357504B (es) | 2012-06-26 | 2013-06-25 | Derivado de feniltriazol y su uso para modular complejo del receptor gabaa. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9206160B2 (OSRAM) |
| EP (1) | EP2877463B1 (OSRAM) |
| JP (1) | JP6224097B2 (OSRAM) |
| KR (1) | KR20150033678A (OSRAM) |
| CN (1) | CN104411699B (OSRAM) |
| AU (1) | AU2013283487C1 (OSRAM) |
| CA (1) | CA2876778A1 (OSRAM) |
| IL (1) | IL236041A (OSRAM) |
| MX (1) | MX357504B (OSRAM) |
| WO (1) | WO2014001281A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10472324B2 (en) | 2014-03-18 | 2019-11-12 | Algiax Pharmaceuticals Gmbh | 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| EP3858965B1 (en) * | 2020-01-28 | 2022-05-11 | The Procter & Gamble Company | Cleaning product |
| WO2021191837A1 (en) | 2020-03-26 | 2021-09-30 | Richter Gedeon Nyrt. | 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa α5 receptor modulators |
| AU2021244926A1 (en) * | 2020-03-26 | 2022-11-03 | Richter Gedeon Nyrt. | Naphthyridine and pyrido(3,4-c)pyridazine derivatives as GABAA a5 receptor modulators |
| EP3992188A1 (en) * | 2020-10-29 | 2022-05-04 | Boehringer Ingelheim International GmbH | Difluoromethyl-pyridin-2-yl triazoles |
| EP4596558A3 (en) * | 2020-08-05 | 2025-11-05 | Boehringer Ingelheim International GmbH | Difluoromethyl-pyridin-2-yl triazoles |
| WO2023016521A1 (zh) * | 2021-08-12 | 2023-02-16 | 上海赛默罗生物科技有限公司 | 取代三唑类衍生物、其制备方法、药物组合物和用途 |
| WO2024023268A1 (en) | 2022-07-29 | 2024-02-01 | F. Hoffmann-La Roche Ag | Characterisation of neurological dysfunction |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2314401A1 (en) | 1997-12-22 | 1999-07-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| JP2009508905A (ja) | 2005-09-19 | 2009-03-05 | エフ．ホフマン−ラ ロシュ アーゲー | ＧＡＢＡＡα５逆アゴニストとしてのイソオキサゾロ誘導体 |
| JP2009511533A (ja) | 2005-10-11 | 2009-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾール誘導体 |
| JP2009514924A (ja) | 2005-11-09 | 2009-04-09 | エフ．ホフマン−ラ ロシュ アーゲー | ３−アリール−イソオキサゾール−４−カルボニル−ベンゾフラン誘導体 |
| AU2006328602B2 (en) | 2005-12-23 | 2012-05-31 | F. Hoffmann-La Roche Ag | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
| BRPI0620760A2 (pt) | 2005-12-27 | 2011-11-22 | Hoffmann La Roche | derivados de aril-isoxazol-4-il-imidazo[1,5]piridina |
| CN101351461B (zh) | 2005-12-27 | 2011-09-07 | 弗·哈夫曼-拉罗切有限公司 | 芳基-异*唑-4-基-咪唑衍生物 |
| WO2007137954A1 (en) | 2006-05-31 | 2007-12-06 | F. Hoffmann-La Roche Ag | Aryl-4-ethynyl-isoxazole derivatives |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| MX2009014001A (es) | 2007-06-22 | 2010-01-28 | Hoffmann La Roche | Derivados de isoxazol-imidazol. |
| CA2706990C (en) | 2007-12-04 | 2016-05-10 | F. Hoffmann-La Roche Ag | Isoxazolo-pyrazine derivatives |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| CA2707648C (en) | 2007-12-04 | 2014-08-12 | F. Hoffmann-La Roche Ag | Isoxazolo-pyridine derivatives |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US8227461B2 (en) | 2009-04-30 | 2012-07-24 | Hoffmann-La Roche Inc. | Isoxazoles |
| ES2601181T3 (es) | 2009-05-05 | 2017-02-14 | F. Hoffmann-La Roche Ag | Derivados de isoxazol-tiazol como agonistas inversos del receptor GABA A para su uso en el tratamiento de trastornos cognitivos |
| CA2760746C (en) | 2009-05-05 | 2017-07-11 | F. Hoffmann-La Roche Ag | Isoxazole-pyrazole derivatives |
| CA2760597C (en) | 2009-05-05 | 2017-08-22 | F. Hoffmann-La Roche Ag | Isoxazole-pyridazine derivatives |
| CA2760166C (en) | 2009-05-05 | 2017-07-18 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
| AU2010244555A1 (en) | 2009-05-07 | 2011-11-03 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives as GABA modulators |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| PH12013500676A1 (en) | 2010-11-05 | 2013-05-06 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| US8466181B2 (en) * | 2010-12-10 | 2013-06-18 | Hoffmann-La Roche Inc. | 1,2,3-triazole-imidazole compounds |
-
2013
- 2013-06-25 KR KR20157001888A patent/KR20150033678A/ko not_active Ceased
- 2013-06-25 US US14/411,331 patent/US9206160B2/en not_active Expired - Fee Related
- 2013-06-25 CN CN201380033706.1A patent/CN104411699B/zh not_active Expired - Fee Related
- 2013-06-25 CA CA2876778A patent/CA2876778A1/en not_active Abandoned
- 2013-06-25 EP EP13732127.9A patent/EP2877463B1/en not_active Not-in-force
- 2013-06-25 MX MX2014014871A patent/MX357504B/es active IP Right Grant
- 2013-06-25 AU AU2013283487A patent/AU2013283487C1/en not_active Ceased
- 2013-06-25 WO PCT/EP2013/063193 patent/WO2014001281A1/en not_active Ceased
- 2013-06-25 JP JP2015519034A patent/JP6224097B2/ja not_active Expired - Fee Related
-
2014
- 2014-12-03 IL IL236041A patent/IL236041A/en not_active IP Right Cessation
-
2015
- 2015-11-16 US US14/942,705 patent/US9931329B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013283487A1 (en) | 2015-01-22 |
| CN104411699A (zh) | 2015-03-11 |
| US9931329B2 (en) | 2018-04-03 |
| US9206160B2 (en) | 2015-12-08 |
| WO2014001281A1 (en) | 2014-01-03 |
| US20150152085A1 (en) | 2015-06-04 |
| IL236041A0 (en) | 2015-02-01 |
| MX2014014871A (es) | 2015-06-17 |
| IL236041A (en) | 2016-09-29 |
| JP2015521642A (ja) | 2015-07-30 |
| EP2877463A1 (en) | 2015-06-03 |
| US20160067234A1 (en) | 2016-03-10 |
| AU2013283487B2 (en) | 2017-05-25 |
| CA2876778A1 (en) | 2014-01-03 |
| AU2013283487C1 (en) | 2018-01-18 |
| CN104411699B (zh) | 2017-06-13 |
| KR20150033678A (ko) | 2015-04-01 |
| EP2877463B1 (en) | 2018-11-07 |
| JP6224097B2 (ja) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX357504B (es) | Derivado de feniltriazol y su uso para modular complejo del receptor gabaa. | |
| PH12014501900A1 (en) | Oxazolidin-2-one compounds and uses thereof as pi3ks inhibitors | |
| GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
| NZ737399A (en) | Ccr2 modulators | |
| PH12014501079A1 (en) | 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions | |
| TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
| GEP201706710B (en) | Imidazopyridazine derivatives as gabaa receptor modulators | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| IN2015DN02912A (OSRAM) | ||
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| IN2014DN11027A (OSRAM) | ||
| MX2014000963A (es) | Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide. | |
| MX2013013436A (es) | Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos. | |
| MX355303B (es) | Compuestos novedosos. | |
| PH12016501764A1 (en) | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators | |
| MX2011008126A (es) | Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina. | |
| MX2014003455A (es) | Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide. | |
| MX2014003584A (es) | Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides. | |
| MX2015005312A (es) | Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12. | |
| MX2016011900A (es) | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. | |
| PH12014500934A1 (en) | Nicotinic receptor non-competitive modulators | |
| TN2014000340A1 (en) | Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors | |
| PH12013501453A1 (en) | Nicotinic receptor non-competitive antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |